Deoxycytidine analog that inhibits DNA synthesis. Metabolized to form gemcitabine triphosphate (dFdCTP) and gemcitabine diphosphate (dFdCDP). dFdCTD inhibits ribonucleotide reductase causing a reduction in cellular nucleotides. dFdCTP is incorporated in DNA resulting in DNA strand termination. Displays antitumor activity in vitro
and in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Evaluation of the antitumor activity of Gemcitabine (2',2'-Difluoro-2'-deoxycytidine).
Hertel et al.
Cancer Res., 1990;50:4417
Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.
Heinemann et al.
Preclinical characteristics of gemcitabine.
Plunkett et al.
Anticancer Drugs, 1995;6:7
The citations listed below are publications that use Tocris products. Selected citations for Gemcitabine hydrochloride include:
Showing Results 1 - 8 of 8